

July 16, 2024

To

BSE Limited
Corporate Relationship Department
25th Floor, P J Towers
Dalal Street, Fort,
Mumbai – 400 001

BSE Scrip Code: 524743

Dear Sir,

Reg : Press Release – Fischer Medical Ventures Ltd Firm Up Marketing Rights of Nanyang Biologics' Transformative Nutraceuticals for India, Middle East & ASEAN region.

We enclose a Press Release regarding "**Fischer Medical Ventures Ltd Firm Up Marketing Rights of Nanyang Biologics' Transformative Nutraceuticals for India, Middle East & ASEAN region**", for dissemination.

Thanking you,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



CIN L24231MH1993PLC288371

Corporate Office : Level 5, Prestige Palladium Bayan, No. 129-140 Greams Road, Chennai, Tamil Nadu, 600006

Registered Office : 104, First Floor Raghuleela Mega Mall, Behind Poisar Depot, Kandivali West Mumbai, Maharashtra, 400067

Fischer Medical Ventures Ltd Firm Up Marketing Rights of Nanyang Biologics' Transformative Nutraceuticals for India, Middle East & ASEAN region

Nanyang Biologics (NYB) aims to disrupt drug discovery industry by leveraging cutting-edge technologies like AI, machine learning, and virtual screening. Through curating a vast Natural Compound Library encompassing over 40,000 compounds from tropical flora, and employing advanced Metagenomics and Metaproteomics Analysis, NYB successfully unveil the therapeutic power hidden in various plants. Their innovative Chemical Fingerprinting techniques elucidate molecular structures, and optimize identification of potent active ingredients. Further powered by AI-driven state-of-the-art Virtual Screening platform DTIGN for bioactivity, NYB could swiftly identify promising drug candidates, reducing discovery lead time and costs substantially



- Fischer Medical Ventures Ltd (Fischer MV), a pioneering force in the healthcare industry, confirmed its collaboration with Singapore company, Nanyang Biologics (NYB), a leading drug discovery company dedicated to create transformative nutraceuticals derived from natural plants & herbs. This strategic partnership aims to revolutionize healthcare industry by delivering innovative, evidence-based products that enhance overall health and well-being, guided by rigorous scientific research and data-driven methodologies.
- Fischer MV (formerly known as Fischer Chemic Ltd) is known for its affordable, and accessible medical diagnostic and imaging technologies, by leveraging cutting-edge innovations and AI-powered software solutions in healthcare. As the first company to indigenously manufacture high-quality Magnetic Resonance Imaging (MRI) systems in India and owning a diverse portfolio of breakthrough diagnostic solutions, Fischer MV is moving into preventative healthcare space with NYB.





- NYB started its drug discovery journey from 2019 and signed a Master Research Collaborative Agreement with the renowned Nanyang Technological University in Singapore in 2021 for a SG\$20M research plan dedicated to develop next-generation AI drug discovery platform. To date, NYB has successfully filed 4 patents; identified 2 cancer drug candidates and developed 4 nutraceutical products. NYB is commercializing its nutraceuticals products this year and plan to start clinical trials for its cancer drug candidates early 2025. Traditional drug discovery processes are slow, costly, and often inefficient, hindering the development of life-saving therapeutics.
- WHO reported that in 2022, there were an estimated 20 million new cancer cases and 9.7 million deaths globally and about 1 in 5 people develop cancer in their lifetime. The global cancer drugs market is projected to reach USD 188.2 billion in 2023 and is expected to grow 13.95% from 2021 to 2028 to USD 361.6 billion (*Source: Statista*). Also prevalent is cardiovascular disease, the leading cause of death worldwide in 2021 with death count reaching 20.5 million globally in 2021 (*Source: World Heart Federation*). Healthcare industry tends to prioritize treatment over prevention, focuses on managing chronic diseases rather than prioritizing preventive measures, despite evidences showing a growing demand for preventive solutions among healthy individuals. Report shows global nutraceuticals market size is valued at USD 487.4 billion in 2020 and projected to grow 8.3% by 2028 (*Source: Grand View Research*).
- NYB aims to address the need for streamlined compound discovery, improved drug development efficiency, and targeted solutions for chronic diseases such as cancer and metabolic disorders, and to foster collaboration across sectors to drive innovation and accelerate the translation of research into impactful clinical applications, reducing time and resource burdens, and ultimately improving global healthcare outcomes.





Currently, NYB have developed products targeted at: Cancer, Cardiovascular Diseases, Fatty Liver & Obesity, namely:

- **CareViva Natural Support**
Harnessing Nature's Remedies for Cancer Care, Innovating Nutraceuticals for Colon Cancer, Breast Cancer, and General Cancer Care.
CareViva Natural Support is designed to support overall health and well-being, especially for individuals at high risk of cancer and those recovering from cancer therapy. Cell division is a normal process that replenishes old or damaged cells. Cancer occurs when the cell division process becomes faulty due to genetic or epigenetic factors, leading to uncontrollable growth and the formation of malignant tumours that can grow quickly and spread to other parts of the body through metastasis. Studies have also shown that gut health is correlated with cancer progression, highlighting the importance of maintaining a healthy gut microbiome. NYB successfully identified and patented the active ingredients used in CareViva Natural Support that targets pathways that are generally more active in cancer cells, promoting natural cell processes that can help maintain good cellular health. This product also enhances gut health, promote microbial diversity, and strengthen the gut barrier.
- **CareViva CardiaViva**
Addresses Atherosclerosis' Root Cause through Targeting Foam Cell Formation
CareViva CardiaViva is a nutraceutical to maintain cardiovascular health and reduce the risk of Atherosclerosis which is the thickening or hardening of the arteries, caused by a buildup of plaque in the inner lining of an artery. Excessive lipid uptake and reduced efflux of cholesterol in macrophage leads to build up of lipid droplets and formation of foam cells, and foam cells deposit on artery walls gradually form plaques. CareViva CardiaViva is formulated to prevent foam cell formation to tackle Atherosclerosis issue by preventing cholesterol and lipid accumulation in macrophages which is more effective than statin, a widely used cholesterol lowering drug. NYB successfully identified and isolated the active compound that can prevent foam cells formation and patent filing is underway.
- **CareViva AdiCare**
An Innovative Nutraceutical that Inhibits Adipogenesis
CareViva AdiCare is a nutraceutical that reduces the risk of obesity, improves adipose health by inducing fat browning. There are two main types of adipose tissues, white fat, and brown fat. White fat is responsible for storage of fat and excessive buildup of white fat leads to obesity. Brown/beige fat, also called “good fat” generates heat by metabolizing fat. Level of brown fat generally regresses with age when our body start to develop shivering thermogenesis but white fat may be induced to form brown fat in the presence of external stimuli, a process called browning. CareViva AdiCare is specially formulated to facilitate transforming white fat into brown fat that has high capacity to burn fat, even more effective than isoproterenol, a potent browning agent. In contrast with appetite suppressant or fat blocker which reduces fat absorption, CareViva AdiCare is a natural solution to stimulate the intrinsic mechanism of fat burning to reduce the risk of obesity.



- **CareViva LivWell**

Promoting Liver Health with Nutraceuticals to Reduce Lipid Accumulation, Combat Hepatic Steatosis, and Alleviate Fatty Liver.

CareViva LivWell is a nutraceutical to support liver health. Around 40% of the global population has non-alcoholic fatty liver disease (NAFLD) and it starts with simple steatosis (>5% fat deposition) that can progress into steatohepatitis with lipotoxic cell death and insulin resistance. Cirrhosis occurs when there is excessive fibrosis and scarring and is a life-threatening condition. Fortunately, fatty liver is reversible before steatohepatitis happens and CareViva LivWell is formulated from a blend of plant extracts to reduce hepatic lipid (simple steatosis) and prevent lipotoxic damage (steatohepatitis). NYB tested the product against several compounds known to be beneficial for NAFLD and found that CareViva LivWell performed better in terms of lipid clearance and prevention of lipotoxicity.

Commenting on the announcement

- **Mr. Ravindran Govindan, Chairman & MD of Fischer MV**, expressed his enthusiasm about the collaboration: “NYB is uniquely positioned to focus on the intersection of nutraceuticals and chronic disease management to provide novel, natural, and preventive solutions to an aging population that is living longer. This, combined with Fischer MV’s expertise in MedTech solutions, robust resources, and strategic network, give us a competitive edge in this rapidly expanding market. We are excited to collaborate with NYB to bring their groundbreaking drug discovery platform to India, the land of Ayurvedic, to work on traditional herbs native to India.”
- **Mr. Roland Ong, Chairman and founder of NYB** is also elated to partner Fischer MV: “In view of the growing demand for preventive care among healthy individuals, we are committed to offer evidence-based, trustworthy solutions for both healthcare providers and the public. Through this collaboration, we are prepared to stand forth and meet the global demand for quality and affordable healthcare, ultimately reducing the burden of chronic diseases worldwide. We are ready to collaborate strategically with esteemed institutions and pharmaceutical companies to pioneer a collaborative ecosystem, driving innovation in chronic disease therapeutics.”
- This strategic partnership with NYB marks a significant milestone in Fischer MV’s mission to provide preventative healthcare and to continue its quest to expand its global sales and offerings in healthcare.



Disclaimer:

This investor release is not an offer to sell any securities or a solicitation to buy any securities of Fischer Medical Ventures Limited (formerly known as Fischer Chemic Ltd) (the "company") or its subsidiaries (together with the company, the "group"). Certain statements in this document may be forward looking statements. These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "projects", "expects", "intends", "may", "will", "or" or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, aims, objectives, goals, future events or intention. Such forward-looking statements are subject to certain risks and uncertainties like government actions, local political or economic developments, technological risks, and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements.

Forward looking statements are not guarantees of future performance including those relating to general business plans and strategy of the Company, its future outlook and growth prospects, and future developments in its businesses and its competitive and regulatory environment. No representation, warranty or undertaking, express or implied, is made or assurance given that such statements, views, projections or forecasts, if any, are correct or that the objectives of the Company will be achieved.

The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. Unless otherwise stated in this Investor Release, the information contained herein is based on management information and estimates. The information contained herein is subject to change without notice and past performance is not indicative of future results. **FISCHERMVL** will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.